The short version
13 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fulvestrant
Fulvestrant · FULVESTRANT 50 mg/mL · Injection · Intramuscular · Glenmark Pharmaceuticals Inc., Usa
NDC 68462-0317-32 · 2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$425.00
Reported to Texas DSHS · 2023 annual filing · Glenmark Pharmaceuticals Inc., USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$513
14 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Glenmark Pharmaceuticals Inc., USAUnited Statesmanufacture
- PCI San Diego, Inc.United Statesmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $691.92 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA207754
- TE code
- AO
- Approval date
- Aug 22, 2019
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedAug 27, 2021Glenmark Pharmaceuticals Inc., USA — Lack of Assurance of Sterility
Manufacturers of Fulvestrant (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Sandoz Inc | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Accord Healthcare Inc. | FULVESTRANT 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| AstraZeneca Pharmaceuticals LP | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Avyxa Pharma, LLC | FULVESTRANT 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories | FULVESTRANT 250 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories. | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., Usa | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Meitheal Pharmaceuticals Inc | FULVESTRANT 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Steroid S.p.A. | FULVESTRANT 25000 g/25000g | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Fulvestrant — NDC 68462-0317-32," retrieved September 3, 2026, https://drugdashboards.com/drug/68462031732.
Free to cite with attribution — see how the data is put together.